Puma Biotechnology (PBYI) Assets Average (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Assets Average came in at $204.5 million in Q1 2026, little changed YoY from $204.8 million in Q1 2025, and down 2.42% on a QoQ basis from $209.6 million in Q4 2025.
Puma Biotechnology (PBYI) Assets Average (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Assets Average data on file, last reported at $204.5 million in Q1 2026.
- Quarterly Assets Average changed 0.13% year-over-year to $204.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204.5 million (changed 0.13% YoY) and the FY2025 annual result came in at $214.8 million, down 3.21% from the prior year.
- Assets Average eased to $204.5 million in Q1 2026, from $209.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $222.3 million in Q1 2024 to a low of $195.5 million in Q2 2025.
- A 5-year average of $207.0 million and a median of $209.2 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average slipped 23.97% — and 2024, when it advanced 6.3%.
- Tracing PBYI's Assets Average over 5 years: stood at $210.4 million in 2022, then increased by 3.16% to $217.1 million in 2023, then retreated by 0.02% to $217.0 million in 2024, then dropped by 3.43% to $209.6 million in 2025, then fell by 2.42% to $204.5 million in 2026.
- The last three Assets Average figures came in at $204.5 million (Q1 2026), $209.6 million (Q4 2025), and $198.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 192.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.72 Mn |
| Mar 31, 2026 | 204.50 Mn |
| Dec 31, 2025 | 209.58 Mn |
| Sep 30, 2025 | 198.89 Mn |
| Jun 30, 2025 | 195.55 Mn |
| Mar 31, 2025 | 204.76 Mn |
| Dec 31, 2024 | 217.03 Mn |
| Sep 30, 2024 | 212.86 Mn |
| Jun 30, 2024 | 209.58 Mn |
| Mar 31, 2024 | 222.34 Mn |
| Dec 31, 2023 | 217.07 Mn |
| Sep 30, 2023 | 202.05 Mn |
| Jun 30, 2023 | 198.38 Mn |
| Mar 31, 2023 | 209.16 Mn |
| Dec 31, 2022 | 210.41 Mn |
| Sep 30, 2022 | 196.21 Mn |
| Jun 30, 2022 | 197.17 Mn |
| Mar 31, 2022 | 213.64 Mn |
| Dec 31, 2021 | 226.44 Mn |
| Sep 30, 2021 | 243.14 Mn |